In a report released on September 14, Robyn Karnauskas from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price target of $84.00. The company’s shares closed yesterday at $58.58.
According to TipRanks, Karnauskas is a 4-star analyst with an average return of 6.3% and a 50.65% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Coherus Biosciences, and Eli Lilly & Co.
In addition to Truist Financial, Bristol-Myers Squibb also received a Buy from Goldman Sachs’s Chris Shibutani in a report issued on September 15. However, on the same day, Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (NYSE: BMY).
The company has a one-year high of $79.43 and a one-year low of $58.86. Currently, Bristol-Myers Squibb has an average volume of 10.5M.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY: